Overview

• Net profit jumped 50% year-on-year to Rs 215.4 crore in Q1 FY26, matching analysts’ estimates.
• Consolidated revenue rose 7.4% to Rs 1,505.6 crore and EBITDA climbed 39% to Rs 367.6 crore, expanding margins to 24.4%.
• The company launched 12 new molecules in regulated markets and filed one ready-to-use bag this quarter as R&D spend reached 4.4% of revenue.
• Jefferies upgraded to hold with a Rs 1,950 target, Citi kept a sell at Rs 1,680, and MOFSL retained buy with a Rs 2,340 target.
• Shares spiked over 6% intraday on Jefferies’ upgrade before paring gains to trade about 2% higher.